CHARGED ALPHATMFrontier AI stock research

TWST · NasdaqGS

Twist Bioscience Corporation

Biotechnology · United States

USD 166.997.3% daily changeQuote 2026-09-18 · USD
Market cap (USD)
US$11.07B
Trailing P/E
Forward P/E
Quarterly revenue growth
23.2%
Trailing net margin
-31.7%
Indicated dividend yield

Snapshot 2026-09-20 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Next earnings: 2026-11-16 (provider estimate, not issuer-confirmed).

Company background

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Company website

Q3 FY2026

Go beyond the headline.

Twist Bioscience (TWST): Revenue +23% And The Loss Got BIGGER. Is TWST a Buy?

Published 2026-08-03

Comparable businesses

TWST peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

No suitable peers with fresh, comparable size data are available. We have not substituted unrelated companies.

Market metrics · missing or inapplicable values shown as —
MetricTWSTTwist Bioscience CorporationSnapshot 2026-09-20Financial period: 2026-06-30
Market capMarket value, converted to USDUS$11.07B
Forward P/EProvider forward earnings estimate
EV / EBITDAEnterprise value / trailing EBITDA
Revenue growthLatest quarter vs prior-year quarter23.2%
Operating marginLatest reported quarter-30.6%
Free cash flow yieldTrailing cash flow / market cap-0.6%
Net debt / EBITDANet debt / trailing EBITDA
Debt / equityTotal debt / positive book equity0.24x
Trailing P/ETrailing twelve-month earnings
Price / bookPrice / positive book equity per share23.48x
EV / salesEnterprise value / trailing revenue24.12x
Earnings growthLatest quarter vs prior-year quarter
Gross marginTrailing twelve months52.0%
Net marginTrailing twelve months-31.7%
Return on equityProvider trailing return; positive equity only-29.6%
Free cash flow marginTrailing free cash flow / revenue-15.0%
Dividend yieldIndicated annual dividend / price
Earnings payoutProvider trailing dividend payout0.0%
Current ratioCurrent assets / current liabilities2.67x
BetaProvider historical market sensitivity2.22

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for TWST

All available reporting periods
Q3 FY20262026-08-03

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.